G1 Therapeutics Inc. and AstraZeneca announced a collaboration to evaluate AstraZeneca’s epidermal growth factor receptor tyrosine kinase inhibitor Tagrisso (osimertinib) in combination with G1’s oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
